Hua Medicine’s Dorzagliatin Approved in China for Type 2 Diabetes
China-based Hua Medicine (HKG: 2552) has announced that its Category 1 drug dorzagliatin has been...
Allergan Aesthetics Launches Juvederm Volite in China’s Boao Lecheng
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has announced the commercial launch of Juvederm Volite...
Shanghai Lange Medtech Partners with Yantai Desheng for Fish-Derived Rotator Cuff Patch
China-based Shanghai Lange Medtech Co., Ltd. has entered into a partnership with compatriot firm Yantai...
Roche Boosts China Investment with Additional RMB 250 Million
Swiss pharmaceutical giant Roche (SWX: ROG) has pledged to invest an additional RMB 250 million...
Boston Scientific Launches Disposable RF Electrode for Chronic Pain in China
Boston Scientific Corporation (NYSE: BSX), a US-based medical device company, has announced the official market...
Rundo Med-Tech Partners with Baidu to Advance Digital Clinical Trials
Shanghai-based Contract Research Organization (CRO) Rundo Pharmaceutical R&D (Shanghai) Co., Ltd (Rundo Med-Tech) has entered...
China’s NMPA Releases 60th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 60th batch of reference drugs for...
China Medical System Licenses Botulinum Toxin from South Korea’s BMI Korea
China Medical System Holdings (CMS; HKG: 0867) has announced the establishment of a licensing agreement...
Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has held a national market...
Betta Pharmaceuticals Raises $140.5M for Drug Industrialization Base in Zhejiang
China’s Betta Pharmaceuticals Co., Ltd. (SHE: 300558) plans to raise RMB 1 billion ($140.5 million)...
China’s Volume-Based Procurement Cuts High-Value Medical Consumables Costs by 84%
The national high-value medical consumables alliance procurement office has released the results of the third...
Everest Medicines’ Xerava Approved in Hong Kong for Complicated Intra-Abdominal Infections
Everest Medicines Limited (HKG: 1952), a China-based biopharmaceutical company, has announced that it has received...
Ascletis Pharma Doses First Patient in Phase II Study of ASC41 for NASH
Ascletis Pharma Inc. (HKG: 1672), a China-based biopharmaceutical company, has announced that the first patient...
Transcenta’s TST004 Receives FDA IND Clearance for IgAN Treatment
China-based Transcenta Holding Ltd (HKG: 6628) has announced that it has received Investigational New Drug...
Connect Biopharma’s CBP-201 Shows Positive Results in Atopic Dermatitis Study
China-based Connect Biopharmaceuticals Ltd has announced the topline results of a pivotal clinical study for...
Kira Pharmaceuticals Gets FDA Green Light for Phase II Study of KP104 in SLE-TMA
Kira Pharmaceuticals, a Sino-US biotech company, has announced that it has received approval from the...
BGI Genomics Added to US Defense Department’s Investment Ban List
BGI Genomics Co., Ltd, a leading Chinese gene sequencing firm, has reportedly been added to...
Humanwell Healthcare’s Remimazolam Receives NMPA Approval for Bronchoscopy Use
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced that it has received another...
Biosyngen’s First-in-Class Drug Candidate BRG01 Accepted for IND Review
Biosyngen has announced that its investigational new drug (IND) filing for the first-in-class (FIC) drug...
Zai Lab Reports Strong Revenue Growth in 2022 Interim Results
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has released its 2022 interim...